adalimumab aqvh

Adalimumab aqvh is a **biosimilar of adalimumab** marketed as **Yusimry**. It is a recombinant human IgG1 monoclonal antibody and **tumor necrosis factor alpha blocker** that binds TNF-alpha and prevents its interaction with cell-surface TNF receptors, thereby suppressing inflammatory signaling. The product was developed by Coherus BioSciences and is manufactured using recombinant DNA technology in Chinese hamster ovary cells. It is administered by **subcutaneous injection** as a sterile, preservative-free, citrate-free solution and is approved for multiple chronic immune-mediated inflammatory disorders, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. Like other adalimumab products, it carries boxed warnings for serious infections and malignancy.

Brand names

Yusimry

Other names

adalimumab-aqvh